Saturday December 7, 2019

The American Cancer Society Recommends Testing For Colon And Rectal Cancer At Age 45

Colon cancer, combined with rectal cancer, is the second leading cause of cancer death in the U.S.

0
//
The group said the initial test does not have to be a colonoscopy.
The American Cancer Society recommends people who are in good health and with a life expectancy of more than 10 years continue regular colorectal cancer screening through the age of 75. Pixabay

The American Cancer Society is recommending people start testing for colon and rectal cancer at age 45, rather than 50 as currently prescribed.

It also recommends people who are in good health and with a life expectancy of more than 10 years continue regular colorectal cancer screening through the age of 75.

“All of these tests are good tests"
“The best test is the test that gets done.”, said the cancer society’s Dr. Rich Wender. Pixabay

The group said the initial test does not have to be a colonoscopy, but instead could be one of several non-invasive tests, such as a home stool test available by prescription.

“All of these tests are good tests, and the choice should be offered to patients,” said the cancer society’s Dr. Rich Wender. “The best test is the test that gets done.”

The change in procedure is based on new information about a marked increase in the incidences of colorectal cancer, particularly rectal cancer, among younger individuals. Experts aren’t sure why there has been a 50 percent increase in cases since 1994.

Read More: According To WHO, Smoking Is A major Cause Of Death And Disease

Most colon cancer occurs in adults 55 and older, and the good news is that rates of cases and deaths have been falling for decades. Colon cancer, combined with rectal cancer, is the second leading cause of cancer death in the U.S.

This year, more than 140,000 Americans are expected to be diagnosed with it, and about 50,000 will die from it. (VOA)

 

Next Story

New Way To Treat Pancreatic Cancer is Here: Researchers

The Decoded mechanism acts efficiently in other types of cancer resistant to current therapies

0
Pancreatic Cancer
Researchers have now harnessed information to efficiently eradicate human Pancreatic Cancer cells in xenografts. Pixabay

Pancreatic Cancer is resistant to all current treatments. Patients have extremely poor chances of surviving for five years after being diagnosed but a new study found that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells.

The study, published in the journal Oncotarget, was conducted with xenografts — transplantations of human pancreatic cancer into immunocompromised mice.

The treatment reduced the number of cancer cells by 90 per cent in the developed tumors a month after being administered.

“In research published in 2017, we discovered a mechanism that causes the self-destruction of human cancer cells during their duplication (mitosis) without affecting normal cells,” said study researcher Malca Cohen-Armon from Tel Aviv University in Israel.

“We have now harnessed this information to efficiently eradicate human pancreatic cancer cells in xenografts. The current results were obtained using a small molecule that evokes this self-destruction mechanism in a variety of human cancer cells,” Cohen-Armon added.

According to the researchers, the mice were treated with a molecule called PJ34, which is permeable in the cell membrane but affects human cancer cells exclusively.

This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death.
Thus, cell multiplication itself resulted in cell death in the treated cancer cells.

Pancreatic Cancer
Pancreatic Cancer is resistant to all current treatments. Patients have extremely poor chances of surviving for five years after being diagnosed but a new study found that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells. Pixabay

A month after being injected with PJ34 daily for 14 days, the pancreatic cancer cells in the tumuors of the treated mice experienced a relative drop of 90 per cent. In one mouse, the tumuor completely disappeared.

“It is important to note that no adverse effects were observed, and there were no changes in the weight gain of the mice, nor in their behaviour,” Cohen-Armon added.

ALSO READ: Protein Deficiency Ordinary Among Indians: Experts

This mechanism acts efficiently in other types of cancer resistant to current therapies.

The molecule PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials begin, the study said. (IANS)